Canadian Adverse Health Events from COVID-19 Vaccines and COVID-19 Statistics – April 10 2021

 

Author: Tracey Young. (April 10, 2021). Canadian Adverse Health Events from COVID-19 Vaccines and COVID-19 Statistics – April 10, 2021. Canadian Advocacy Centre for Health, Safety and Justice. Retrieved from: https://canadianadvocacycentre.blogspot.com/2021/04/canadian-adverse-health-events-from_10.html.

Introduction

COVID-19 Vaccines have been getting administered in Canada since December 2020. Around the world countries are reporting a staggering range of post-vaccine Adverse Health events, and deaths associated with all of the COVID-19 vaccines that have received Interim, or Emergency authorization in their respective countries. 

The Canadian government has reported 27 deaths have occurred after COVID19 vaccines were administered in Canada. Upon further medical investigation and review, the Canadian government reported 16 deaths were not associated with the COVID-19 vaccine. They have also reported 11 of these deaths continue to be under investigation. Anecdotal reports of post-vaccine deaths are being reported across Canada. Official statistical data being reported in Canada does not appear to be capturing all of the post-vaccine AEFI's, or mortalities. 

In this article I will provide an overview of Canadian government statistical data and information about Adverse Events Following Immunization (AEFI) with COVID-19 vaccines, vaccine injuries and reactions that have been associated with these vaccines up to April 2nd, 2021. 

Figure 4. Most frequently reported adverse events up to and including April 2, 2021 (n=9,071)

Canada: COVID Vaccines: Adverse Events Following Immunization (AEFI) Statistical Data and Information

COVID-19 Vaccine Safety - Government of Canada

Source: https://health-infobase.canada.ca/covid-19/vaccine-safety/

Adverse Events Following Immunization (AEFI) Statistical Data

Dates: From mid-December 2020 – March 26^th, 2021

Note: Detailed AEFI Breakdowns can be found under Figure 4 (scroll down to the bottom of the page and click on the link).

⮚ COVD Vaccine Doses Administered in Canada: 5,897,445

• Previous: Feb. 12th: 1,221,539; Feb. 19th: 1,402,139; Feb. 26th:1,778,405; March 5th: 2,255,174; March 12th: 2,830,164; March 19th: 3,729,312; March 26th: 4,800,931

⮚ 3,089 AEFI’s (.052% of all doses administered); 

• Previous: Feb. 12th: 957; Feb. 19th: 1235; ; Feb. 26th:1591; March 5th: 1923; March 12th: 1922; ; March 19th: 2,530; March 26th: 2,859

⮚ 27 Deaths 

• 16 reported to not be linked to vaccine; 11 are still under investigation
• Previous: March 26th: 24 (13 not linked; 11 under investigation); 

⮚ 421 Serious AEFI’s (.007% of all doses administered); 

• Previous: Feb. 12th: 140; Feb. 19th: 167; Feb. 26th:194; ; March 5th: 214; March 12th: 287; March 19th: 320; March 26th: 384

⮚ 2,668 Non-serious AEFI’s (.05% of all doses administered); 

• Previous: Feb. 12th: 817Feb. 19th:1068; Feb. 26th:1397; ; March 5th:1709; March 12th:1922; March 19th: 2,210; March 26th: 2,475 

⮚ 182 New Adverse events reported in the last week

• Previous: March 26th: 247

⮚ # of reported adverse events was highest among females and those aged 18 to 49.

⮚ 52.4 reports per 100,000 doses administered (out of a total of 3,089 reports) up to and including April 2, 2021.

Figure 2. Number of adverse event reports by vaccine name up to andincluding April 2, 2021 (n=3,085*)

Definition of Serious AEFI:

An event is considered serious if it:

• results in death
• is life-threatening (an event/reaction in which the patient was at real, rather than hypothetical, risk of death at the time of the event/reaction)
• requires in-patient hospitalization or prolongation of existing hospitalization
• results in persistent or significant disability/incapacity, or
• results in a congenital anomaly/birth defect

Anaphylaxis: Among the 421 serious reports, the most frequently reported adverse event was anaphylaxis.

Special Note Regarding AstraZeneca COVID-19 vaccine: There have been reports in Europe of blood clots associated with low levels of blood platelets (thrombocytopenia) following vaccination with the AstraZeneca COVID-19 vaccine. 

⮚ Following European reports of blood clots associated with low levels of blood platelets (thrombocytopenia), the National Advisory Committee on Immunization and the Chief Medical Officers of Health recently recommended that AstraZeneca COVID-19 vaccines should not be used in adults under age 55.

Source: Government of Canada. (April 10, 2021). Coronavirus Disease (COVID-19) Epidemiology Update. Retrieved from: https://health-infobase.canada.ca/covid-19/vaccine-safety/. 

Canadian COVID-19 Statistics: April 10, 2021

➤ 2.8% of Canadians have been diagnosed with COVID-19 in 1+ year

➤️.2% Active cases in the Canadian population

➤ 91% Recovered 

➤ 5% hospitalization rate

➤️ 3.8% + rate for 19+ million Canadians tested

➤️ .06% of Canadian population have been reported to die with COVID-19

➤ 96% of those who have died with CV-19 were over 60 years old, with pre-existing health conditions that are associated with more severe cases

United States

Source: Open VAERS. (April 2, 2021). VAERS COVID Reports (COVID-19 Vaccine Adverse Events Report System Data. Retrieved from: https://www.openvaers.com/covid-data.

Front line Worker Testimonies: COVID-19 Vaccine Adverse Reactions. Retrieved from: https://drive.google.com/file/d/1YK0JR_lFy88Zu3rcC3L5NvL_Xr3ib6zY/view.

Copyright © 2021.Tracey Young/Canadian Advocacy Centre for Health, Safety and Justice. All Rights Reserved.
_________________________________________________

#COVID19 #COVID19Canada #COVIDvaccines #COVID19vaccines #Canada #DutytoWarn #HealthPromotion #HealthPrevention #InformedConsent #cdnpoli #canpoli